Subscribe To

Price Alert Latest News Economic Calendar News

ARAY / Accuray's (ARAY) CEO Josh Levine on Q3 2022 Results - Earnings Call Transcript

Accuray Incorporated (NASDAQ:ARAY ) Q3 2022 Earnings Conference Call April 27, 2022 4:30 PM ET Company Participants Ken Mobeck – Vice President-Finance Josh Levine – Chief Executive Officer Suzanne Winter – President Brandy Green – Interim Chief Financial Officer Conference Call Participants Brooks O'Neil – Lake Street Capital Markets Marie Thibault – BTIG Josh Jennings – Cowen Frank Pinal – Jefferies Jason Wittes – Loop Capital Operator Good afternoon, and welcome to the Accuray Third Quarter Fiscal 2022 Financial Results Conference Call. [Operator instructions] Please note this event is being recorded. Read More

Demo Live Account See Partner Details

Content Topics

Accuray

ARAY

Josh

Levine

2022

Results

Earnings

Call

Accuray s

aray

Transcript

Stock

Posted: Apr 27 2022, 20:26

Author Name: Seeking Alpha

ARAY News

By Seeking Alpha
October 6, 2023

With Chinese Type B Approval In Hand, 'Now Or Never' Approaches For Accuray

Accuray's China JV recently received approval to sell its locally-produced Tomo C rad-onc system for China's Type B market - an opportunity that manag

By Zacks Investment Research
October 5, 2023

Accuray's (ARAY) Tomo C Radiation System Gets Approval in China

Accuray's (ARAY) Tomo C radiation therapy system will enable medical care teams to provide personalized and highly precise treatments.

By Zacks Investment Research
October 3, 2023

Accuray's (ARAY) New Offering to Boost Radiation Treatment Plans

Accuray's (ARAY) latest offering is likely to improve radiation treatment.

By Zacks Investment Research
September 8, 2023

Why Is Accuray (ARAY) Down 15.2% Since Last Earnings Report?

Accuray (ARAY) reported earnings 30 days ago. What's next for the stock?

By Seeking Alpha
August 19, 2023

Accuray Incorporated - Impressive Growth As Orders Expands

Accuray Incorporated has shown impressive growth in its share price and revenues, making it an attractive investment opportunity in the healthcare equ

By Zacks Investment Research
August 15, 2023

Accuray's (ARAY) Treatment Options to be Boosted Post FDA's Nod

Accuray's (ARAY) latest regulatory approval is likely to improve breast cancer treatment.

By Zacks Investment Research
August 11, 2023

New Strong Sell Stocks for August 11th

NGLOY, ARAY and BANR have been added to the Zacks Rank #5 (Strong Sell) List on August 11, 2023.

By Zacks Investment Research
August 10, 2023

Accuray (ARAY) Q4 Earnings and Revenues Lag Estimates

Accuray (ARAY) reports a solid fiscal fourth quarter top line on the back of robust segmental performances.

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.